Compounds > nsc 289487
Page last updated: 2024-12-07

nsc 289487

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

asterriquinone: from Aspergillus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100329
CHEMBL ID1966265
CHEBI ID51881
SCHEMBL ID847899
MeSH IDM0109327

Synonyms (25)

Synonym
NCI60_002372
nsc-289487
2,4-dione, 2,5-bis[1-(1,1-dimethyl-2-propenyl)-1h-indol-3-yl]-3,6-dihydroxy-
2,5-bis-[1'-(1'',1''-dimethyl-2''-propenyl)-indol-3'-yl]-3,6-dihydroxy-1,4-benzoquinone
2,5-cyclohexadiene-1,4-dione, 2,5-bis[1-(1,1-dimethyl-2-propenyl)-1h-indol-3-yl]-3,6-dihydroxy-
2,5-bis[1-(1,1-dimethylallyl)indol-3-yl]-3,6-dihydroxy-1,4-benzoquinone
60696-52-8
NSC289487 ,
asterriquinone
2,5-bis[1-(1,1-dimethylallyl)-1h-indol-3-yl]-3,6-dihydroxy-1,4-benzoquinone
2,5-dihydroxy-3,6-bis[1-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]cyclohexa-2,5-diene-1,4-dione
CHEBI:51881 ,
2,5-dihydroxy-3,6-bis[1-(2-methylbut-3-en-2-yl)indol-3-yl]cyclohexa-2,5-diene-1,4-dione
nsc 289487
jv64rb1ejo ,
unii-jv64rb1ejo
demethylasterriquinone a1
demethyl-asterriquinone a1
2,5-cyclohexadiene-1,4-dione, 2,5-bis(1-(1,1-dimethyl-2-propenyl)-1h-indol-3-yl)-3,6-dihydroxy-
SCHEMBL847899
CHEMBL1966265
DTXSID90209505
Q27122909
2,5-cyclohexadiene-1,4-dione, 2,5-bis(1-(1,1-dimethyl-2-propen-1-yl)-1h-indol-3-yl)-3,6-dihydroxy-
2,5-bis(1-(1,1-dimethyl-2-propen-1-yl)-1h-indol-3-yl)-3,6-dihydroxy-2,5-cyclohexadiene-1,4-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
asterriquinonesCompounds containing the asterriquinone skeleton.
dihydroxy-1,4-benzoquinonesA hydroxybenzoquinone that is any 1,4-benzoquinone in which two of the substituents on the quinone ring are hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (15.38)18.7374
1990's7 (53.85)18.2507
2000's4 (30.77)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2,5-dichlorohydroquinone
2,5-dichlorohydroquinone: a 2,4,5-TCP metabolite. 2,5-dichlorohydroquinone : A dichlorohydroquinone that is hydroquinone substituted by chloro groups at positions 2 and 5 respectively.		2.0110dichlorohydroquinonebacterial xenobiotic metabolite
bromine
Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.		2.0110diatomic bromine
l 783281
L 783281: structure in first source		3.5120
terrequinone a
terrequinone A: from Aspergillus; structure in first source. terrequinone A : A bisindole alkaloid that is quinone bearing a hydroxy substituent at position 2, a 3,3-dimethylallyl group at position 5 and two indol-3-yl groups at positions 3 and 6, one of which is carrying a 1,1-dimethylallyl group at position 2.		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		02.3620
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.6830
Insulin Sensitivity
[description not available]		02.9210
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		02.9210
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.9210